• RITA (NSC 652287): Applied Workflows in Renal Carcinoma Rese

  2026-05-09

  RITA (NSC 652287) stands out as a precise MDM2-p53 interaction inhibitor, enabling robust p53 activation and selective cytotoxicity in renal carcinoma models. This guide translates advanced in vitro and in vivo findings into practical workflows, with troubleshooting insights for maximizing translational impact.

• OM-MSCs Mitigate Golgi Stress Post-Ischemia via PI3K/Akt/mTO

  2026-05-08

  This study demonstrates that olfactory mucosa mesenchymal stem cells (OM-MSCs) alleviate Golgi apparatus stress after cerebral ischemia/reperfusion injury by activating the PEDF-PI3K/Akt/mTOR pathway. The findings clarify the role of OM-MSCs in neuroprotection, providing a mechanistic foundation for stem cell-based therapies targeting subcellular stress responses in stroke.

• Probenecid: Applied Strategies for Multidrug Resistance & Ne

  2026-05-08

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) enables researchers to overcome multidrug resistance in tumor models and dissect neuroprotective mechanisms in cerebral ischemia/reperfusion injury. This guide delivers advanced, workflow-oriented protocols and troubleshooting insights, leveraging the unique inhibition profile and storage characteristics of APExBIO’s Probenecid.

• Caffeine in Translational Research: From Metabolic Modulatio

  2026-05-07

  This thought-leadership article unpacks the mechanistic versatility of caffeine (1,3,7-trimethylpurine-2,6-dione) as a tool for translational researchers. It integrates evidence from metabolic, oncological, and neurobiological domains, highlighting protocol essentials and strategic guidance. The discussion benchmarks caffeine’s validated applications—such as cancer cell line inhibition and energy balance modulation—against emerging trends in targeted small molecule development. Drawing on recent advances in myocardial protection via ALDH2 activators, it charts a forward-looking agenda for leveraging caffeine’s mechanistic profile in high-impact translational workflows.

• HyperTrap Heparin HP Column: High-Resolution Stemness Purifi

  2026-05-07

  The HyperTrap Heparin HP Column empowers precise purification of growth factors, coagulation proteins, and nucleic acid enzymes—essential for dissecting cancer stemness and signaling. Its optimized HyperChrom Heparin HP Agarose matrix and exceptional chemical resilience streamline workflows in challenging breast cancer research models.

• Synthetic Viability in ERCC1-Deficient Lung Cancer with ICLs

  2026-05-06

  Heyza et al. (2019) reveal that ERCC1-deficient lung cancer cells exhibit synthetic viability in response to DNA interstrand crosslinks, with p53 status critically modulating sensitivity to platinum-based chemotherapy. These findings clarify why ERCC1 is an unreliable biomarker for cisplatin response and highlight the interplay between DNA repair, cell cycle control, and therapeutic resistance.

• Disulfiram (SKU A4015): Reliable Proteasome Inhibition for C

  2026-05-06

  This article presents scenario-driven, evidence-based guidance on using Disulfiram (SKU A4015) for reproducible cancer and cell viability assays. It explores protocol optimization, data interpretation, and vendor reliability, underlining how Disulfiram’s validated mechanistic and workflow attributes address common lab challenges.

• Hoechst 33342: Precision Nuclear Staining for Live-Cell Anal

  2026-05-05

  Hoechst 33342 enables high-contrast, live-cell nuclear visualization, optimizing workflows in cell cycle and apoptosis research. Its robust DNA specificity and flexible protocol parameters set it apart from other bis-benzimidazole fluorescent dyes for dynamic cell biology applications.

• Bardoxolone Methyl: Applied Redox Modulation in Cancer & CKD

  2026-05-05

  Bardoxolone methyl (CDDO methyl ester) enables precision modulation of Nrf2 and NF-kB pathways, making it a cornerstone in oxidative stress and inflammation research. This article translates the latest redox biology breakthroughs into actionable protocols and troubleshooting strategies for cancer, kidney disease, and advanced redox assays.

• Ibrexafungerp and Caspofungin Efficacy Against Resistant C.

  2026-05-04

  Wiederhold et al. demonstrate that ibrexafungerp, a triterpenoid β-(1,3)-D-glucan synthase inhibitor, exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, including when therapy is delayed. The study benchmarks this performance alongside caspofungin, informing strategies for antifungal agent selection in resistant Candida research.

• Neuroligin 1 Loss Drives Repetitive Behaviors via PKC in Str

  2026-05-04

  This study reveals that Neuroligin 1 deletion in D2-expressing striatal neurons induces autistic-like repetitive behaviors by hyperactivating the PKC signaling pathway. The findings clarify a cellular and molecular mechanism underlying restrictive and repetitive behaviors (RRBs) in ASD and highlight potential PKC-targeted interventions.

• Paclitaxel (Taxol): Quantitative Assay Optimization in Cance

  2026-05-03

  Explore the pivotal role of Paclitaxel (Taxol) in optimizing quantitative assays for cancer research. This article uniquely bridges rigorous in vitro evaluation with advanced protocol design, offering practical insights for translational oncology.

• Biotin-tyramide: Precision Signal Amplification in IHC & ISH

  2026-05-02

  Biotin-tyramide empowers researchers to achieve ultra-sensitive, spatially resolved detection in immunohistochemistry, in situ hybridization, and proximity labeling. Leveraging enzyme-mediated signal amplification, this APExBIO reagent enables robust mapping of protein interactions and low-abundance targets—delivering clarity that standard detection methods cannot match.

• Letrozole (SKU A1307): Reliable Aromatase Inhibition in Brea

  2026-05-01

  This article explores real-world laboratory challenges in estrogen pathway studies and demonstrates how Letrozole (SKU A1307) enables reproducible, sensitive, and cost-effective aromatase inhibition. Drawing on scenario-driven Q&A, it equips biomedical scientists with validated protocols and actionable guidance for reliable breast cancer research workflows.

• CBD Attenuates Orofacial Inflammatory Pain via Multi-Domain

  2026-05-01

  This study demonstrates that cannabidiol (CBD) robustly reduces both sensory and affective components of orofacial inflammatory pain in murine models, acting through peripheral and central endocannabinoid pathways. The research highlights CBD’s translational potential for comprehensive pain management and provides a mechanistic basis for future targeted investigations in pain modulation.

16165 records 1/1078 page Next 12345 下5页 Last page